TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
16 10월 2023 - 9:00PM
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology
company committed to more effectively treating cancer using RNA
therapeutics, today reported successful treatment of preclinical
melanoma tumors using its immunotherapy candidate, TTX-RIGA. The
study showed a significant inhibition of tumor growth.
TTX-RIGA, an innovative immunotherapeutic
candidate built around TransCode’s proprietary TTX delivery
platform is designed to activate the immune system against tumor
cells potentially resulting in effective treatment of multiple
primary, metastatic, and recurrent cancers. TTX-RIGA is designed to
work by binding to an intracellular receptor called RIG-I (retinoic
acid-inducible gene I). TransCode believes this could result in
targeted activation of innate immunity in the tumor
microenvironment. Recent developments in the use of pattern
recognition receptors (PRRs), such as RIG-I, aim to harness the
innate power of the immune system to treat cancer. TransCode
believes that understanding how to recruit PRRs, such as RIG-I, in
a tumor-selective manner is critical for clinical
applications.
In a mouse model of melanoma, systemic injection
of TTX-RIGA demonstrated that the therapeutic candidate was
effective in reducing primary tumor growth. Remarkably, it also
elicited an immune response against secondary recurrent tumors,
inhibiting their growth by 70%. This stands in contrast to
intratumorally-administered standard RIG-I activators, which have
demonstrated efficacy confined to the primary tumor. TransCode’s
approach is designed to achieve persistent cell-mediated immunity
by targeted activation of innate immunity in cancer cells within
the tumor microenvironment. TransCode believes that its approach
helps establish RIG-I as a clinically relevant target in oncology
for a variety of solid tumors including melanoma, glioblastoma
multiforme (GBM), pancreatic, colorectal and breast cancer, and
especially tumors that are prone to recurrence after initial
treatment.
“The strategy we are employing with TTX-RIGA
moves us closer to making this immunotherapeutic approach
clinically relevant in oncology because it achieves targeted
activation of innate immunity in the tumor microenvironment in the
context of systemic agonist injection,” commented Zdravka Medarova,
PhD, co-founder and CTO of TransCode. “As with prior studies, we
believe the data from this animal study further support advancement
of TTX-RIGA into clinical studies. The opportunity for systemic,
yet tumor cell-selective, activation of innate immunity using our
therapeutic design could represent an important step towards
effective application of similar immunotherapeutic mechanisms for
cancer therapy in the clinical setting.”
Recent developments in the use of pattern
recognition receptors (PRRs) aim to harness the innate power of the
immune system for cancer therapy. TransCode seeks to address this
challenge by developing a strategy for tumor-selective activation
of an immune response specific to cancer cells using systemic
administration with its proprietary nanoparticle delivery system,
TTX. TransCode anticipates that immune activation will not be
triggered in healthy tissues that do not express the target, but
rather will be selectively activated only in tumors and metastases
that do express the target. Similar competitive
immunotherapeutics have been shown to induce complete tumor
regressions in animals and have triggered immunity against the
tumor. However, those therapies are often administered directly
into the tumor to avoid the toxicity resulting from activation of
an adverse immune response against healthy tissues. Administration
directly into the tumor has not proven clinically effective due to
limited access to the tumor cells, especially in the context of
disseminated metastatic cancer.
“We believe that demonstrating successful in
vivo results with TTX-RIGA is an important step in the preclinical
development process and further de-risks our pipeline that includes
multiple RNA approaches including RNAi, PRR, mRNA vaccines and gene
editing with CRISPR, all of which utilize our proprietary delivery
platform,” said Michael Dudley, co-founder and CEO of
TransCode.
About TransCode
Therapeutics
TransCode is an RNA oncology company created on
the belief that cancer can be more effectively treated using RNA
therapeutics. Using its iron oxide nanoparticle delivery platform,
the Company has created a portfolio of drug candidates designed to
target a variety of tumor types with the objective of significantly
improving patient outcomes. The Company’s lead therapeutic
candidate, TTX-MC138, is focused on treating metastatic cancer,
which is believed to cause approximately 90% of all cancer deaths
totaling over nine million per year worldwide. The Company believes
that TTX-MC138 has the potential to dramatically improve clinical
outcomes in a range of cancers, including breast, pancreatic,
ovarian and colon cancer, glioblastomas and others. Another of the
Company’s drug candidates, TTX-siPDL1, focuses on treating tumors
by targeting a protein called Programmed death-ligand 1 (PD-L1).
TransCode also has three cancer-agnostic programs: TTX-RIGA, an
RNA–based agonist of the retinoic acid-inducible gene I designed to
drive an immune response in the tumor microenvironment; TTX-CRISPR,
a CRISPR/Cas9–based therapy platform for the repair or elimination
of cancer-causing genes inside tumor cells; and TTX-mRNA, an
mRNA-based platform for the development of cancer vaccines designed
to activate cytotoxic immune responses against tumor cells.
Forward-Looking Statements
This release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, statements
concerning the results of preclinical studies of TTX-RIGA in
melanoma and other tumor types, statements concerning expected
clinical results of TransCode’s therapeutic candidates, statements
concerning the results of RNA research, statements concerning the
potential for treating cancer with RNA therapeutics, statements
concerning the timing and outcome of expected regulatory filings
and clinical trials, including the first-in-human clinical trial of
TTX-MC138, and whether this study will demonstrate
proof-of-mechanism, and statements concerning TransCode’s portfolio
of drug candidates and TTX technology platform generally. Of note,
TransCode has identified conditions and events that raise
substantial doubt about its ability to continue operations in the
near-term. If the company is unable to raise additional capital to
fund its operations, it will likely need to consider cost reduction
strategies, which may include, among others, amending, delaying,
limiting, reducing, or terminating its development programs, and it
may need to seek an in-court or out-of-court restructuring of its
liabilities. Any forward-looking statements in this press release
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: the risk
associated with drug discovery and development; the risk that the
results of our planned clinical trials will not be consistent with
our pre-clinical studies or expectations; risks associated with the
timing and outcome of TransCode’s planned regulatory submissions;
risks associated with TransCode’s planned clinical trials for its
product candidates; risks associated with obtaining, maintaining
and protecting intellectual property; risks associated with
TransCode’s ability to enforce its patents against infringers and
defend its patent portfolio against challenges from third parties;
the risk of competition from other companies developing products
for similar uses; risks associated with TransCode’s financial
condition and its need to obtain additional funding to support its
business activities, including TransCode’s ability to continue as a
going concern; risks associated with TransCode’s dependence on
third parties; and risks associated with the COVID-19 coronavirus.
For a discussion of these and other risks and uncertainties, and
other important factors, any of which could cause TransCode’s
actual results to differ from those contained in or implied by the
forward-looking statements, see the section entitled “Risk Factors”
in TransCode’s Annual Report on Form 10-K for the year ended
December 31, 2022, as well as discussions of potential risks,
uncertainties and other important factors in any subsequent
TransCode filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release;
TransCode undertakes no duty to update this information unless
required by law.
For more information, please contact:
TransCode Therapeutics, Inc.Alan Freidman, VP Investor
Relationsalan.freidman@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
TransCode Therapeutics (NASDAQ:RNAZ)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024